Anti-fibulin-3 antibodies and uses thereof
Embodiments described herein provide anti-fibulin-3 antibodies, recombinant proteins that bind specifically to fibulin-3, compositions and the treatment methods comprising these antibodies and recombinant proteins.
1. A T-cell or a Natural Killer (NK) cell comprising a chimeric antigen receptor (CAR) protein comprising an antigen-binding region of an anti-Fibulin-3 monoclonal antibody, the antigen-binding region comprising the amino acid sequences SEQ ID NO: 5-10.
2. The T cell or the NK cell of claim 1 , wherein the CAR protein is labeled with an agent.
3. The T cell or the NK cell of claim 2 , wherein the agent is selected from the group consisting of a radioisotope, fluorescent compound, bioluminescent compound, chemiluminescent compound, metal chelator, and enzyme.
4. The T cell or the NK cell of claim 2 , wherein the agent is a cytotoxic or a therapeutic agent.
5. The T cell or the NK cell of claim 4 , wherein the cytotoxic agent is selected from the group consisting of ricin, ricin A-chain, doxorubicin, daunorubicin, taxol, ethidium bromide, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicine, dihydroxy anthracenedione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha-sarcin, gelonin, mitogellin, phenomycin, enomycin, curicin, calicheamicin, Saponaria officinalis inhibitor, and glucocorticoid.
6. The T cell or the NK cell of claim 3 , wherein the radioisotope is selected from the group consisting of 212 Bi, 131 I, 131 In, 90 Y, and 186 Re.
7. A composition comprising a population of T cells or Natural Killer cells of claim 1 .
8. The composition of claim 7 further comprising a pharmaceutically acceptable excipient.
9. The T cell or the NK cell of claim 1 , wherein the anti-Fibulin-3 monoclonal antibody is mAb428.3C11.